Literature DB >> 11739604

The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK).

L Edwards1, D Fishman, P Horowitz, N Bourbon, M Kester, P Ernsberger.   

Abstract

We sought to further elucidate signal transduction pathways for the I1-imidazoline receptor in PC12 cells by testing involvement of protein kinase C (PKC) isoforms (betaII, epsilon, zeta), and the mitogen-activated protein kinases (MAPK) ERK and JNK. Stimulation of I1-imidazoline receptor with moxonidine increased enzymatic activity of the classical betaII isoform in membranes by about 75% and redistributed the atypical isoform into membranes (40% increase in membrane-bound activity), but the novel isoform of PKC was unaffected. Moxonidine and clonidine also increased by greater than two-fold the proportion of ERK-1 and ERK-2 in the phosphorylated active form. In addition, JNK enzymatic activity was increased by exposure to moxonidine. Activation of ERK and JNK followed similar time courses with peaks at 90 min. The action of moxonidine on ERK activation was blocked by the I1-receptor antagonist efaroxan and by D609, an inhibitor of phosphatidylcholine-selective phospholipase C (PC-PLC), previously implicated as the initial event in I1-receptor signaling. Inhibition or depletion of PKC blocked activation of ERK by moxonidine. Two-day treatment of PC12 cells with the I1/alpha2-agonist clonidine increased cell number by up to 50% in a dose related manner. These data suggest that ERK and JNK, along with PKC, are signaling components of the I1-receptor pathway, and that this receptor may play a role in cell growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739604     DOI: 10.1046/j.1471-4159.2001.00632.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

Review 1.  Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?

Authors:  Andrew Holt
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

2.  Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor.

Authors:  Po-Sheng Yang; Hung-Tsung Wu; Hsien-Hui Chung; Chun-Ta Chen; Chin-Wen Chi; Ching-Hua Yeh; Juei-Tang Cheng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

3.  α- and β-Adrenergic receptors differentially modulate the emission of spontaneous and amphetamine-induced 50-kHz ultrasonic vocalizations in adult rats.

Authors:  Jennifer M Wright; May R S Dobosiewicz; Paul B S Clarke
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

4.  Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands.

Authors:  Andrew Holt; Barbara Wieland; Glen B Baker
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

Review 5.  Agmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependence.

Authors:  Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2007-07-25       Impact factor: 5.046

6.  Presynaptic I1-imidazoline receptors reduce GABAergic synaptic transmission in striatal medium spiny neurons.

Authors:  Mitsuo Tanabe; Yurika Kino; Motoko Honda; Hideki Ono
Journal:  J Neurosci       Date:  2006-02-08       Impact factor: 6.167

7.  I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline.

Authors:  Yaron D Barac; Orit Bar-Am; Esti Liani; Tamar Amit; Luba Frolov; Elena Ovcharenko; Itzchak Angel; Moussa B H Youdim; Ofer Binah
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.